Stock Events

Stock Events

NeuroPace 

$13.15
0
-$0.18-1.35% Today

Statistics

Day High
13.33
Day Low
13.15
52W High
-
52W Low
-
Volume
134
Avg. Volume
-
Mkt Cap
438M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.22
-0.18
-0.13
-0.08
Expected EPS
-0.223511
Actual EPS
N/A

Financials

-33.97%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
159.81MRevenue
-54.28MNet Income

Analyst Ratings

$19.25Average Price Target
The highest estimate is 22.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NPCE.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap116.33B
Medtronic offers a range of neurostimulation devices that compete directly with NeuroPace's RNS System for epilepsy treatment.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories provides various neuromodulation devices, including those for epilepsy, which competes with NeuroPace's solutions.
LivaNova
LIVN
Mkt Cap2.87B
LivaNova operates in the neuromodulation space with its VNS Therapy System, which is used for the treatment of drug-resistant epilepsy and directly competes with NeuroPace's offerings.
Smith & Nephew
SNN
Mkt Cap15.61B
Smith & Nephew offers advanced medical devices in various areas, including neuromodulation, competing in the broader market that NeuroPace targets.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific Corporation designs and manufactures medical devices, including neuromodulation products that could be used in applications similar to those of NeuroPace.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its extensive pharmaceutical solutions, offers medications for epilepsy, competing in the broader epilepsy treatment market against NeuroPace's device-focused approach.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. produces several drugs for neurological conditions, including epilepsy, offering an alternative to NeuroPace's neuromodulation devices.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its subsidiary DePuy Synthes, offers neurosurgical and neuromodulation products that could compete with NeuroPace's epilepsy treatment solutions.
Zoetis
ZTS
Mkt Cap63.86B
Zoetis, primarily focused on animal health, including neurological conditions in animals, represents a less direct form of competition in the broader neurology market.

About

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Show more...
CEO
ISIN
US6412881053

Listings

XNAS
US
NPCE
BOATS
BOATS
NPCE.BOATS

0 Comments

Share your thoughts

FAQ

What is NeuroPace stock price today?▼
The current price of NPCE.BOATS is $13.15 USD — it has decreased by -1.35% in the past 24 hours. Watch NeuroPace stock price performance more closely on the chart.
What is NeuroPace stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NeuroPace stocks are traded under the ticker NPCE.BOATS.
What is NeuroPace market cap?▼
Today NeuroPace has the market capitalization of 438M
When is the next NeuroPace earnings date?▼
NeuroPace is going to release the next earnings report on May 07, 2026.
What were NeuroPace earnings last quarter?▼
NPCE.BOATS earnings for the last quarter are -0.08 USD per share, whereas the estimation was -0.16 USD resulting in a +48.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NeuroPace revenue for the last year?▼
NeuroPace revenue for the last year amounts to 159.81M USD.
What is NeuroPace net income for the last year?▼
NPCE.BOATS net income for the last year is -54.28M USD.
When did NeuroPace complete a stock split?▼
NeuroPace has not had any recent stock splits.